The intestinal microbiome in spondyloarthritis

• Published in: Current opinion in rheumatology Vol. 27; no. 4; p. 319
• Main Authors: Gill, Tejpal, Asquith, Mark, Rosenbaum, James T, Colbert, Robert A
• Format: Journal Article
• Language: English
• Published: United States 01.07.2015
• Subjects: Animals; Arthritis, Psoriatic - immunology; Arthritis, Psoriatic - microbiology; Disease Models, Animal; Dysbiosis - physiopathology; Gastrointestinal Microbiome - immunology; Humans; Inflammatory Bowel Diseases - immunology; Inflammatory Bowel Diseases - microbiology; Intestines - immunology; Intestines - microbiology; Spondylarthritis - immunology; Spondylarthritis - microbiology; Spondylitis, Ankylosing - immunology; Spondylitis, Ankylosing - microbiology
• ISSN: 1531-6963
• DOI: 10.1097/bor.0000000000000187

Microbial dysbiosis in the gut is emerging as a common component in various inflammatory disorders including spondyloarthritis (SpA). The depth of this influence has begun to be realized with next-generation sequencing of the gut microbiome providing unbiased assessment of previously uncharted bacterial populations. Decreased numbers of Firmicutes, a major phyla of gut commensals, especially the species Faecalibacterium prausnitzii and Clostridium leptum have been found in various inflammatory disorders including SpA and inflammatory bowel disease (IBD), and could be an important link between SpA and gut inflammation. Multiple studies in ankylosing spondylitis, psoriatic arthritis, juvenile SpA, and animal models of SpA are revealing common bacterial associations among these diseases as well as IBD. We are beginning to appreciate the complex relationship between the gut microbiome and host immune regulation and dysregulation in health and disease. Potentially important differences have been revealed in SpA, but cause and effect relationships remain far from established. Many critical questions remain to be answered before we can apply new knowledge to improve therapeutics in SpA.